PolTREG has received a PLN 51.4 million ($12.5M) grant recommendation from the Polish Agency for Enterprise Development to support the development of a groundbreaking therapy for multiple sclerosis (MS).

This non-refundable funding will enable PolTREG to initiate Phase I/IIa clinical trials in 2025 for two forms of MS: relapsing-remitting (RRMS) and primary progressive (PPMS). With clinical protocols already in place, the company is well-positioned to start the trials as soon as they receive regulatory approval.

Multiple sclerosis affects nearly 3 million people worldwide, making it one of the most common neurological diseases among young adults. Current treatments mainly focus on symptom relief and slowing disease progression. PolTREG’s approach aims to redefine MS treatment by targeting the underlying mechanisms of this autoimmune condition.

The coming months will be filled with significant clinical milestones. Soon, the first therapies will be administered to patients in a Phase II clinical trial for PolTREG’s lead asset, PTG-007, in children with stage 1 (presymptomatic) type 1 diabetes.